Hanall Biopharma Co., Ltd. (KRX:009420)
64,600
+300 (0.47%)
At close: Aug 28, 2026
Hanall Biopharma Revenue
Hanall Biopharma had revenue of 44.28B KRW in the quarter ending June 30, 2026, with 8.83% growth. This brings the company's revenue in the last twelve months to 162.66B, up 8.38% year-over-year. In the year 2025, Hanall Biopharma had annual revenue of 155.18B with 11.69% growth.
Revenue (ttm)
162.66B
Revenue Growth
+8.38%
P/S Ratio
20.17
Revenue / Employee
535.06M
Employees
304
Market Cap
3.28T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 155.18B | 16.24B | 11.69% |
| Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
| Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
| Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
| Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yuhan | 2.28T |
| Daewoong | 2.12T |
| GC Biopharma | 2.04T |
| Chong Kun Dang Pharmaceutical | 1.74T |
| Hanmi Pharm. | 1.66T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.06T |